Natera, Inc. current report, 08 August 2017

Natera, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Natera, Inc. on August 8, 2017. The filing discloses the entry into a material definitive agreement involving a new senior secured term loan facility.

Key Financial Metrics and Debt

  • Total Facility Size: $100,000,000 senior secured term loan.
  • Initial Drawdown: $75,000,000 received on August 8, 2017.
  • Remaining Availability: $25,000,000 available upon request by December 31, 2018.
  • Interest Rate: 8.75% plus the higher of the LIBO Rate or 1.00%.
  • Maturity Date: August 8, 2024.
  • Prepayment Penalty: Repayment Premium ranging from 2.5% to 12.5% depending on the prepayment date.
  • Equity Consideration: Issuance of 300,000 shares of common stock to the lender (OrbiMed) as a fee.
  • Collateral: Secured by substantially all assets, including intellectual property.

Material Changes and Covenants

The filing represents a significant change in the company's capital structure through the addition of substantial debt. The Credit Agreement includes specific financial covenants requiring Natera to maintain minimum net revenues both as a condition precedent to the loans and as an ongoing covenant. The agreement also imposes customary negative covenants restricting investments, asset dispositions, and additional indebtedness.

Risks and Contingencies

  • Events of Default: Include non-payment, covenant violations, bankruptcy, material adverse changes, and change of control.
  • Consequences of Default: May result in acceleration of obligations and an interest rate increase of 3.00% for the duration of the default.
  • Emerging Growth Company Status: Natera is an emerging growth company and has elected not to use the extended transition period for new accounting standards.

Investor Verification Checklist

  • Verify the company's current net revenue levels against the minimum net revenue covenants required by the Credit Agreement.
  • Confirm the dilution impact of the 300,000 shares issued to OrbiMed.
  • Review the specific terms regarding the $25,000,000 additional drawdown availability and conditions.
  • Assess the company's ability to service the debt given the high interest rate structure (8.75% + LIBO/1.00%).